PMID,Title,Journal,Year
40830314,Glucagon-Like Peptide-1 Receptor Agonist Therapy Does Not Increase Gastrointestinal Adverse Events in Patients with Inflammatory Bowel Disease.,Digestive diseases and sciences,2025
40687404,Semaglutide-Induced Small Bowel Pseudo-Obstruction and Ileitis in a Patient With Type 2 Diabetes: A Case Report.,Cureus,2025
39717004,Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease.,The American journal of gastroenterology,2025
39516435,Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease.,Digestive diseases and sciences,2024
38767015,Effectiveness and safety of a GLP-1 agonist in obese patients with inflammatory bowel disease.,Revista espanola de enfermedades digestivas,2024
38642103,Effectiveness and Safety of Semaglutide for Weight Loss in Patients With Inflammatory Bowel Disease and Obesity.,Inflammatory bowel diseases,2025
38288136,Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications.,Therapeutic advances in endocrinology and metabolism,2024
